NASDAQ:ONCO Onconetix 5/20/2024 Earnings Report $4.51 -0.32 (-6.63%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings History Onconetix EPS ResultsActual EPS-$544.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOnconetix Revenue ResultsActual Revenue$0.70 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOnconetix Announcement DetailsQuarterDate5/20/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsOnconetix's next earnings date is estimated for Wednesday, August 27, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Onconetix Earnings HeadlinesOnconetix, Inc. Announces Positive Decision by Nasdaq Hearings PanelJune 16, 2025 | globenewswire.comOnconetix, Inc. Announces Approval of 1-for-85 Reverse Stock Split by StockholdersJune 13, 2025 | nasdaq.comForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.July 15 at 2:00 AM | Brownstone Research (Ad)Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of StockholdersJune 11, 2025 | globenewswire.comOnconetix faces potential Nasdaq delisting over filing delaysMay 24, 2025 | investing.comOnconetix receives additional delisting notice from NasdaqMay 23, 2025 | finance.yahoo.comSee More Onconetix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email. Email Address About OnconetixOnconetix (NASDAQ:ONCO) (NASDAQ: ONCO) is a clinical-stage biotechnology company dedicated to the discovery and development of novel targeted cancer therapies. The company’s research platform integrates advanced molecular targeting with precision delivery systems to address unmet needs in oncology. Onconetix’s lead candidate is in Phase I clinical trials for aggressive solid tumors, with additional preclinical programs focused on hematologic malignancies and immuno-oncology combinations. By leveraging its proprietary conjugation technology, the company aims to minimize off-target effects while maximizing antitumor efficacy. In addition to its internal R&D pipeline, Onconetix has established strategic partnerships with academic medical centers and contract research organizations to accelerate its drug discovery efforts. These collaborations span medicinal chemistry optimization, translational biomarker development, and GMP manufacturing scale-up. The company’s multidisciplinary team of scientists and clinicians works to advance candidates through preclinical toxicology and into human studies, emphasizing a streamlined development path designed to deliver proof-of-concept data efficiently. Founded in 2016 and headquartered in San Diego, California, Onconetix conducts research activities primarily in North America, with subsidiary research operations in Europe to support early-stage clinical programs. The company’s global footprint is further extended through licensing agreements in Asia, where Onconetix collaborates with regional partners to facilitate clinical development and regulatory filings. Onconetix’s leadership team is led by CEO Dr. Emily Chen, a biopharmaceutical veteran with over two decades of experience in oncology drug development, alongside CFO Robert Li and Chief Scientific Officer Dr. Sandra Morales.Written by Jeffrey Neal JohnsonView Onconetix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft Earnings3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor Hopes Upcoming Earnings ASML (7/16/2025)Bank of America (7/16/2025)The Goldman Sachs Group (7/16/2025)Johnson & Johnson (7/16/2025)Kinder Morgan (7/16/2025)Morgan Stanley (7/16/2025)Progressive (7/16/2025)Prologis (7/16/2025)The PNC Financial Services Group (7/16/2025)Cintas (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
